← Leaderboards
Daniel J Canney
Praeventix, Llc
$1,809,545
Attributed
$6,133,635
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,133,635 · 5
By mechanism
R44$5,276,290 · 2
R43$857,345 · 3
Top collaborators
- Douglas Anthony Pippin8 shared
- Benjamin Blass7 shared
- Ellen Ann Walker3 shared
- Carlos A Barrero1 shared
Most similar at Praeventix, Llc
Same institution · by research overlap
- Benjamin Blass$1,717,697
- Carlos A Barrero$91,848
Others in their field
Other Emerging Leaders on “Chronic”
- Jeffrey Reich · Sparian Biosciences, Inc.$21,671,295
- Priyamvada Acharya · Duke University$20,941,151
- Dale Sandler · Social And Scientific Systems, Inc.$18,360,118
- Steven Schachter · Massachusetts General Hospital$18,327,380
- Suparna Goswami · Univ Of North Carolina Chapel Hill$16,919,767
- Abraham Aizer Brody · New York University School Of Medicine$15,928,507
Research focus
ChronicEfficacy StudyIn VivoDrug KineticsSerotoninSerotonin 7 ReceptorReportingLeadDoseSeriesAcutePlasmaBrainProgramsPharmaceutical PreparationsLinkScreeningPermeabilityIn VitroPharmacologyMedicalBrain RegionBiological AvailabilityOral
Grant awards (8)
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2024 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2023 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$320,000
R44 · FY2022 · DA
Novel 5-HT7 Antagonists for the Treatment of Pruritus$275,544
R43 · FY2022 · AR
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2019 · DK
In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model$350,000
R43 · FY2019 · DA
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2018 · DK
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$231,801
R43 · FY2017 · DK